Virtually two years following biotechnology shares began to tumble, executives at modest and midsize corporations in the room are lastly accepting that share prices aren’t bouncing again whenever soon.
With reality placing in, it is a buyer’s sector for businesses wanting for acquisitions and partnerships, according to numerous of the pharmaceutical and healthcare technologies executives who gathered at this year’s
J.P. Morgan
health care investor meeting, which wrapped up in San Francisco on Thursday.
Virtually two years following biotechnology shares began to tumble, executives at modest and midsize corporations in the room are lastly accepting that share prices aren’t bouncing again whenever soon.
With reality placing in, it is a buyer’s sector for businesses wanting for acquisitions and partnerships, according to numerous of the pharmaceutical and healthcare technologies executives who gathered at this year’s
J.P. Morgan
health care investor meeting, which wrapped up in San Francisco on Thursday.
